The influence of propofol on vomiting induced by apomorphine. 1995

A Hvarfner, and B Hammas, and S E Thörn, and M Wattwil
Department of Anesthesia and Intensive Care, Orebro Medical Center Hospital, Sweden.

It has been proposed that propofol has antiemetic effects even in nonsedative doses. The aim of this study was to investigate whether propofol influences vomiting induced by the dopamine agonist apomorphine. Ten healthy male volunteers received apomorphine infusion (1 mg/min) until vomiting was induced on four different occasions in a randomized order: a) during propofol infusion (2.4 +/- 0.7 mg.kg-1.h-1, mean +/- SD) at a sedation score of Grade 2-3 on a 5-grade scale; b) during midazolam infusion (0.13 +/- 0.04 mg.kg-1.h-1) at a sedation score of Grade 2-3 on a 5-grade scale; c) after a single nonsedating bolus dose propofol 0.4 mg/kg; and d) during infusion of normal saline. The amount of apomorphine needed to induce vomiting was increased after sedation with propofol (P = 0.005) as well as midazolam (P = 0.001). There was no difference in the sensitivity to apomorphine between these sedative regimens. The nonsedating single bolus propofol did not change the sensitivity to apomorphine compared to the saline infusion. We conclude that propofol given in a nonsedative dose has no effect on apomorphine-induced vomiting. However, the total amount of apomorphine given to induce vomiting was significantly larger during propofol sedation than during saline infusion. This was probably an effect of sedation inasmuch as a similar result was achieved during midazolam sedation.

UI MeSH Term Description Entries
D008297 Male Males
D008874 Midazolam A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH. Dormicum,Midazolam Hydrochloride,Midazolam Maleate,Ro 21-3981,Versed,Hydrochloride, Midazolam,Maleate, Midazolam,Ro 21 3981,Ro 213981
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001058 Apomorphine A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use. Apokinon,Apomorphin-Teclapharm,Apomorphine Chloride,Apomorphine Hydrochloride,Apomorphine Hydrochloride Anhydrous,Apomorphine Hydrochloride, Anhydrous,Apomorphine Hydrochloride, Hemihydrate,Britaject,Apomorphin Teclapharm
D014839 Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH. Emesis
D015742 Propofol An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS. Disoprofol,2,6-Bis(1-methylethyl)phenol,2,6-Diisopropylphenol,Aquafol,Diprivan,Disoprivan,Fresofol,ICI-35,868,ICI-35868,Ivofol,Propofol Abbott,Propofol Fresenius,Propofol MCT,Propofol Rovi,Propofol-Lipuro,Recofol,2,6 Diisopropylphenol,ICI 35,868,ICI 35868,ICI35,868,ICI35868
D016292 Conscious Sedation A drug-induced depression of consciousness during which patients respond purposefully to verbal commands, either alone or accompanied by light tactile stimulation. No interventions are required to maintain a patent airway. (From: American Society of Anesthesiologists Practice Guidelines) Sedation, Conscious,Sedation, Moderate,Moderate Sedation

Related Publications

A Hvarfner, and B Hammas, and S E Thörn, and M Wattwil
February 1956, Clinical science,
A Hvarfner, and B Hammas, and S E Thörn, and M Wattwil
January 1970, Clinical pharmacology and therapeutics,
A Hvarfner, and B Hammas, and S E Thörn, and M Wattwil
September 1954, Lancet (London, England),
A Hvarfner, and B Hammas, and S E Thörn, and M Wattwil
March 1957, The Journal of pharmacology and experimental therapeutics,
A Hvarfner, and B Hammas, and S E Thörn, and M Wattwil
August 1953, Canadian journal of medical sciences,
A Hvarfner, and B Hammas, and S E Thörn, and M Wattwil
March 1955, The Journal of pharmacology and experimental therapeutics,
A Hvarfner, and B Hammas, and S E Thörn, and M Wattwil
December 1966, Revista espanola de fisiologia,
A Hvarfner, and B Hammas, and S E Thörn, and M Wattwil
January 1957, Atti della Accademia dei fisiocritici in Siena. Sezione medico-fisica,
A Hvarfner, and B Hammas, and S E Thörn, and M Wattwil
January 1988, Comparative biochemistry and physiology. A, Comparative physiology,
A Hvarfner, and B Hammas, and S E Thörn, and M Wattwil
January 1968, Acta anaesthesiologica,
Copied contents to your clipboard!